Cephalon Receives Approval to Market Modafinil for Shift Work Sleep Disorder in Germany
01-Sep-2005
"Germany is the third European country to approve modafinil for the treatment of shift work sleep disorder and to recognize the need to treat it. This new indication capitalizes on the strong clinical data surrounding this medication and allows us to improve the quality of life of the people suffering from this debilitating disorder," said Alain Aragues, President, Cephalon Europe.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.